Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Abou‐Alfa, Ghassan K.; Puig, Óscar; Daniele, Bruno; Kudo, Masatoshi; Merle, Philippe; Park, Joong-Won; Ross, Paul; Péron, Jean Marie; Ebert, Oliver; Chan, Stephen L.; Poon, Tung Ping; Colombo, M.; Okusaka, Takuji; Ryoo, Baek Yeol; Mínguez, Beatriz; Tanaka, Takayoshi; Ohtomo, Toshihiko; Ukrainskyj, Stacey M.; Boisserie, Frédéric; Rutman, Olga; Chen, Ya Chi; Xu, Chao; Shochat, Eliezer; Jukofsky, Lori; Reis, Bernhard; Chen, Gong; Laurenzio, Laura Di; Lee, Ray; Yen, Chia Jui

doi:10.1016/j.jhep.2016.04.004

Cited by 97 publications

(84 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A phase I study have already shown its tolerability at doses of 20 mg/kg/week, with little response [34,35] . In a randomized placebo-controlled phase II clinical trial conducted subsequently in patients with advanced HCC previously treated, codrituzumab showed no clinical benefit in this population [36] .…”

Section: Glypican-3mentioning

confidence: 88%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Section: Glypican-3mentioning

confidence: 88%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Researchers and clinicians have been even trying to combine both sorafenib and classical chemotherapy treatment options. Sorafenib in combination with chemotherapy (doxorubicin) as shown by Abou-Alfa et al [5] has shown promising results. Abou Alfa et al [7] conducted a study examining the efficacy and safety of sorafenib with doxorubicin in patients with advanced HCC, and followed that median survival was 13,7 months (95%CI 8,9-not reached) was attained in comparison to 6,5 months (4,5-9,9) among patients treated with doxorubicin alone(p=0,006).…”

Section: Discussionmentioning

confidence: 99%

“…Trials with many targeted therapies except with Sorafenib have proved to be negative trials. For example codrituzumab [5], Linifarib, Sunitinib, Brivanib , cixutumumab [6][7][8][9], Everolismus showed no significant increase in overall survival (OS). Only Sorafenib as shown in the SHARP (1) trial in the West and as shown in Oriental trial conducted in the East showed statistically significant (3 months) increase in OS [10][11][12][13][14].…”

Section: Systemic Therapies In Advanced Hepatocellular Cancermentioning

confidence: 99%

FOLFOX4 as First Line Treatment in Advanced Hepatocellular Cancer, when Sorafenib is not Available: Can it be an Option?

Vyas¹

2016

CTOIJ

View full text Add to dashboard Cite

“…Recently, Codrituzumab, a humanized monoclonal antibody targeting GPC3 and interacting with CD16/FcγRIIIa has been tested in cohorts with advanced HCC (125 patients) in a randomized phase II trial with placebo (60 patients). However, the outcome of the study did not have beneficial effect and higher dose or patient selection with higher biomarkers were suggested for better therapeutic outcome (Abou-Alfa et al, 2016) (Fig. 3 and Table 2).…”

Section: Current Treatment Modalities For Hepatocellular Carcinomamentioning

confidence: 99%

Recent advances in hepatocellular carcinoma therapy

Dutta

Mahato

2017

Pharmacology & Therapeutics

229

169

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.

show abstract

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Cited by 97 publications

References 28 publications

Performance of different biomarkers for the management of hepatocellular carcinoma

Performance of different biomarkers for the management of hepatocellular carcinoma

FOLFOX4 as First Line Treatment in Advanced Hepatocellular Cancer, when Sorafenib is not Available: Can it be an Option?

Recent advances in hepatocellular carcinoma therapy

Contact Info

Product

Resources

About